Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Oral anticoagulant therapy

G E Raskob1

  • 1Department of Medicine and Biostatistics and Epidemiology, University of Oklahoma Health Sciences Center, Oklahoma City 73190, USA.

Current Opinion in Hematology
|September 1, 1996
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Oral apixaban for the treatment of venous thromboembolism in cancer patients: results from the AMPLIFY trial.

Journal of thrombosis and haemostasis : JTH·2015
Same author

Thrombosis: a major contributor to global disease burden.

Arteriosclerosis, thrombosis, and vascular biology·2014
Same author

Comparison of idrabiotaparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: the Borealis-Atrial Fibrillation Study.

Journal of thrombosis and haemostasis : JTH·2014
Same author

Apixaban after hip or knee arthroplasty versus enoxaparin: efficacy and safety in key clinical subgroups.

Journal of thrombosis and haemostasis : JTH·2013
Same author

Apixaban versus enoxaparin for thromboprophylaxis after hip or knee replacement: pooled analysis of major venous thromboembolism and bleeding in 8464 patients from the ADVANCE-2 and ADVANCE-3 trials.

The Journal of bone and joint surgery. British volume·2012
Same author

Effect of obesity on outcomes after fondaparinux, enoxaparin, or heparin treatment for acute venous thromboembolism in the Matisse trials.

Journal of thrombosis and haemostasis : JTH·2007
Same journal

Dynamic myeloid suppressor states in cancer and inflammation and their therapeutic potential.

Current opinion in hematology·2026
Same journal

Factor XIa inhibition for the prevention of thrombosis: mechanism, clinical trial signals, and indication-specific positioning.

Current opinion in hematology·2026
Same journal

Nutrition as a regulator of hematopoietic stem cell biology and transplantation.

Current opinion in hematology·2026
Same journal

From biomimicry to clinical actionability: rethinking high-shear thrombosis as a mechanobiological system.

Current opinion in hematology·2026
Same journal

Bidirectional relationship between metabolic and thrombotic disease mechanisms.

Current opinion in hematology·2026
Same journal

The dual role of the brain-derived neurotrophic factor as a regulator of hemostasis and thrombotic risk.

Current opinion in hematology·2026
See all related articles

Oral anticoagulant therapy, particularly warfarin, is effective for preventing blood clots and stroke, especially in atrial fibrillation patients. Monitoring International Normalized Ratio (INR) ensures safe and effective treatment within specific ranges.

Area of Science:

  • Cardiology
  • Pharmacology
  • Thrombosis

Background:

  • Oral anticoagulant therapy is a crucial antithrombotic treatment for various medical indications.
  • Monitoring prothrombin time using the International Normalized Ratio (INR) is standard practice.

Purpose of the Study:

  • To outline the recommended therapeutic INR ranges for different indications.
  • To compare the efficacy of warfarin versus aspirin for stroke prevention in atrial fibrillation.
  • To discuss warfarin management in elderly patients and the potential of patient self-monitoring.

Main Methods:

  • Review of existing data on oral anticoagulant therapy, focusing on warfarin and aspirin.
  • Analysis of recommended INR ranges for specific patient populations and indications.

Related Experiment Videos

  • Evaluation of stroke prevention strategies in atrial fibrillation.

    • Main Results:

    • Recommended INR range is 2 to 3 for most indications, and 2.5 to 3.5 for mechanical heart valves and myocardial infarction.
    • Warfarin is generally more effective than aspirin for stroke prevention in atrial fibrillation.
    • Close monitoring is advised for elderly patients on warfarin; patient self-monitoring may be effective in selected cases.

    Conclusions:

    • Warfarin is the preferred oral anticoagulant for stroke prevention in most atrial fibrillation patients.
    • Aspirin serves as an alternative when warfarin is contraindicated or for low-risk patients.
    • Optimal INR monitoring and patient selection are key for safe and effective oral anticoagulant therapy.